A Clinical Trial of KTX-2001 for Prostate Cancer
Phase 1
144
about 2.9 years
18+
Male only
13 sites in CA, FL, MN +6
What this study is about
This trial is testing a new medication called KTX-2001 in men with advanced prostate cancer that has become resistant to other treatments. The goal is to see if the drug is safe, determine the best dose, and understand how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take KTX-2001
- 2.Take KTX-2001 + Darolutamide (NUBEQA®)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
darolutamide
oral (Oral Tablet)
Primary: Percentage of patients with dose-limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Secondary: Overall safety profile including adverse events, Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Oncology